ASCO 2022 | What to look forward to in breast cancer at ASCO 2022?

Kevin Kalinsky, MD, MS, Winship Cancer Institute of Emory University, Atlanta, GA, highlights key updates in breast cancer to be discussed at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, including the results of DESTINY-Breast04 (NCT03734029) evaluating trastuzumab deruxtecan in HER2-low breast cancer, as well as updates on the use of sacituzumab govetican in patients with triple-negative breast cancer (TNBC). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.